Zhonglun Law Firm advised Immorna on the formation of a joint venture with Junshi Biosciences to jointly develop self-replicating and conventional mRNA innovative drugs and vaccines
Zhonglun Law Firm advised Immorna on the formation of a joint venture with Junshi Biosciences to jointly develop self-replicating and conventional mRNA innovative drugs and vaccines
On July 19, 2021, Immorna, an emerging biotechnology company focusing on development and optimization of mRNA and delivery vector process as well as the R&D of nucleic acid innovative drugs, signed a joint venture contract with Junshi Biosciences (1877.HK, 688180.SH), the first domestic “H+A" listed biopharmaceutical company to establish a joint venture to collaborate globally on the development and commercialization of innovative drug programs in oncology, infectious diseases, rare disease etc. based on mRNA technology platforms and other technology platforms. Pursuant to the joint venture contract, Junshi Biosciences will contribute RMB 799 million, and Immorna will contribute the right to use relevant technology and intellectual property rights in relation to the mRNA platform to the joint venture. Both parties hold 50% of the equity interests in the joint venture.
Zhong Lun Law Firm acted as the external legal advisor for Immorna and was comprehensively involved in the negotiation and signing of the Project, as well as assisting the parties in reviewing, revising and finalizing the relevant transaction documents, including the Joint Venture Contract, the Articles of Association and the Technology Licensing Agreement.The legal team of the Project was led by Audry Li and Helen Cheng. The key members include Grace Gao and Shuman Zhang.